Ventrus Biosciences Inc. Reaches New 12-Month High at $3.92 (VTUS)
Shares of Ventrus Biosciences (NASDAQ:VTUS) hit a new 52-week high during trading hours on Tuesday, AnalystRatingsNetwork reports. The company traded as high as $3.92 and last traded at $3.77, with a volume of 234,647 shares trading hands. The stock had previously closed at $3.72.
Separately, analysts at Cantor Fitzgerald raised their price target on shares of Ventrus Biosciences from $5.00 to $6.00 in a research note to investors on Wednesday, November 13th. They now have a “buy” rating on the stock.
Ventrus Biosciences has a 52-week low of $1.91 and a 52-week high of $3.92. The stock has a 50-day moving average of $3.15 and a 200-day moving average of $2.78. The company’s market cap is $79.7 million.
Ventrus Biosciences, Inc (NASDAQ:VTUS) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.